Please login to the form below

Not currently logged in
Email:
Password:

Halaven

This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.

NICE set to reject wider use of Eisai’s Halaven

NICE set to reject wider use of Eisai’s Halaven

NICE set to reject wider use of Eisai’ s Halaven. Issues draft guidance recommending against second-line use in breast cancer. ... Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to

Latest news

More from news
Approximately 8 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. “ ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics